Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis
M Talpaz, JJ Kiladjian - Leukemia, 2021 - nature.com
Myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF) is characterized by
cytopenias, marrow fibrosis, constitutional symptoms, extramedullary hematopoiesis …
cytopenias, marrow fibrosis, constitutional symptoms, extramedullary hematopoiesis …
Emerging patterns of somatic mutations in cancer
IR Watson, K Takahashi, PA Futreal, L Chin - Nature Reviews Genetics, 2013 - nature.com
Recent advances in technological tools for massively parallel, high-throughput sequencing
of DNA have enabled the comprehensive characterization of somatic mutations in a large …
of DNA have enabled the comprehensive characterization of somatic mutations in a large …
SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in Janus kinase inhibitor–naïve patients with myelofibrosis
RA Mesa, JJ Kiladjian, JV Catalano, T Devos… - Journal of Clinical …, 2017 - ascopubs.org
Purpose We evaluated the efficacy and safety of momelotinib, a potent and selective Janus
kinase 1 and 2 inhibitor (JAKi), compared with ruxolitinib, in JAKi-naïve patients with …
kinase 1 and 2 inhibitor (JAKi), compared with ruxolitinib, in JAKi-naïve patients with …
Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial
CN Harrison, AM Vannucchi, U Platzbecker… - The Lancet …, 2018 - thelancet.com
Summary Background The Janus kinase (JAK) inhibitor ruxolitinib is the only approved
therapy for patients with symptomatic myelofibrosis. After ruxolitinib failure, however, there …
therapy for patients with symptomatic myelofibrosis. After ruxolitinib failure, however, there …
Development and validation of an International Prognostic Score of thrombosis in World Health Organization–essential thrombocythemia (IPSET-thrombosis)
T Barbui, G Finazzi, A Carobbio, J Thiele… - Blood, The Journal …, 2012 - ashpublications.org
Accurate prediction of thrombosis in essential thrombocythemia (ET) provides the platform
for prospective studies exploring preventive measures. Current risk stratification for …
for prospective studies exploring preventive measures. Current risk stratification for …
Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia
G Rotunno, C Mannarelli, P Guglielmelli… - Blood, The Journal …, 2014 - ashpublications.org
Mutations in the calreticulin (CALR) gene were recently discovered in patients with essential
thrombocythemia (ET) lacking the JAK2 V617F and MPL W515 mutations, but no information …
thrombocythemia (ET) lacking the JAK2 V617F and MPL W515 mutations, but no information …
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms …
F Passamonti, F Cervantes… - Blood, The Journal …, 2010 - ashpublications.org
Age older than 65 years, hemoglobin level lower than 100 g/L (10 g/dL), white blood cell
count greater than 25× 109/L, peripheral blood blasts 1% or higher, and constitutional …
count greater than 25× 109/L, peripheral blood blasts 1% or higher, and constitutional …
Gli1+ mesenchymal stromal cells are a key driver of bone marrow fibrosis and an important cellular therapeutic target
RK Schneider, A Mullally, A Dugourd, F Peisker… - Cell stem cell, 2017 - cell.com
Bone marrow fibrosis (BMF) develops in various hematological and non-hematological
conditions and is a central pathological feature of myelofibrosis. Effective cell-targeted …
conditions and is a central pathological feature of myelofibrosis. Effective cell-targeted …
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
F Cervantes, B Dupriez, A Pereira… - Blood, The Journal …, 2009 - ashpublications.org
Therapeutic decision-making in primary myelofibrosis (PMF) is becoming more challenging
because of the increasing use of allogeneic stem cell transplantation and new …
because of the increasing use of allogeneic stem cell transplantation and new …
CD169+ macrophages provide a niche promoting erythropoiesis under homeostasis and stress
A role for macrophages in erythropoiesis was suggested several decades ago when
erythroblastic islands in the bone marrow, composed of a central macrophage surrounded …
erythroblastic islands in the bone marrow, composed of a central macrophage surrounded …